I-Acute Lymphoblastic Leukemia(T-ALL)-08

Isiguli:Yeshe

Ubulili:Owesilisa

Ubudala: Iminyaka engu-45

Ubuzwe: IsiShayina

UkuxilongwaI-Acute Lymphoblastic Leukemia (T-ALL)

Xhumana nathi

U-Yesheng waseFujian uthe, "Ukube ngangazi nge-CAR-T e-Ludaopei, ngabe ngifike kusenesikhathi."

NgoSepthemba 2017, u-Yesheng waqala ukuqubuka ebusweni, okwasakazeka kancane kancane futhi kwahlanganiswa kwaba neziqephu. Ngo-February 28, 2018, ukuhlolwa komnkantsha kwaqinisekisa "i-acute T-cell lymphoblastic leukemia" ngemva kwezifundo eziningi ze-chemotherapy, nokuhlolwa kwensalela okungalungile. Yonke imithi yayekwa ngoJuni 2019.

NgoMeyi 2021, u-Yesheng wethula izixuku esifundeni somlomo-pharyngeal kanye nama-lymph nodes entamo. Ukuhlolwa kabusha komnkantsha kwaqinisekisa ukuphindeka ngokuphelele kwe-leukemia. NgoMeyi 28, u-Yesheng wadluliselwa eMnyangweni Wesibili We-Hematology esibhedlela saseLudaopei ukuze angeniswe. Ngemva kokuhlolwa okuphelele, ukuxilongwa kwabuyekezwa ku-"acute leukemia (T/myeloid biphenotypic)."

Umjikelezo owodwa we-chemotherapy awuzange ubangele ukukhululeka emnkantsheni wamathambo. Ngomhla zingama-27 kuNtulikazi, u-Yesheng wathola i-CD7 CAR-T cell therapy, elandelwa yi-chemotherapy ehlanganiswe nokwelashwa kwamaseli e-CD7 CAR-T. Ezinsukwini eziyishumi nanhlanu ngemva kokumpontshelwa, ukuhlolwa komnkantsha kwabonisa isifo esibi se-residual, ne-grade 1 cytokine release syndrome (CRS) ukusabela futhi akukho ukusabela okungalungile kwesistimu yezinzwa.